
Quarterly report 2026-Q1
added 05-07-2026
Outset Medical Net Debt 2011-2026 | OM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Outset Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 63 M | 75.2 M | 63.2 M | 24.4 M | -151 M | -286 M | -7.86 M | 105 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | -286 M | -14.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.64 | -8.85 % | $ 330 M | ||
|
EDAP TMS S.A.
EDAP
|
-26.7 M | $ 4.17 | 0.97 % | $ 156 M | ||
|
Apyx Medical Corporation
APYX
|
3.52 M | $ 4.05 | -7.11 % | $ 166 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-12.4 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-77.2 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 7.66 | 1.19 % | $ 1.15 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.3 | -3.77 % | $ 1.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 17.72 | -1.01 % | $ 416 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
-10.2 M | $ 5.54 | -4.97 % | $ 66.2 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.27 | -5.22 % | $ 51.7 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.5 | -8.16 % | $ 31.1 M | ||
|
LivaNova PLC
LIVN
|
-282 M | $ 70.0 | -2.33 % | $ 3.82 B | ||
|
MiMedx Group
MDXG
|
-148 M | $ 3.56 | 0.28 % | $ 526 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 11.07 | -3.4 % | $ 397 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-51 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.01 | - | $ 17.1 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
-2.42 M | $ 0.91 | 2.49 % | $ 38.1 M | ||
|
Orthofix Medical
OFIX
|
78.5 M | $ 12.01 | -2.28 % | $ 476 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 35.68 | -2.25 % | $ 302 M | ||
|
Butterfly Network
BFLY
|
-130 M | $ 3.83 | -6.59 % | $ 811 M | ||
|
Insulet Corporation
PODD
|
218 M | $ 147.46 | -0.82 % | $ 10.4 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Sintx Technologies
SINT
|
-898 K | $ 2.27 | -5.62 % | $ 6.3 M | ||
|
Globus Medical
GMED
|
-511 M | $ 76.64 | -0.74 % | $ 10.4 B | ||
|
Profound Medical Corp.
PROF
|
-55 M | $ 6.97 | -3.19 % | $ 211 M | ||
|
Stryker Corporation
SYK
|
11 B | $ 306.76 | 0.41 % | $ 117 B | ||
|
CONMED Corporation
CNMD
|
802 M | $ 35.49 | -2.34 % | $ 1.1 B | ||
|
Tactile Systems Technology
TCMD
|
-75.4 M | $ 22.74 | -1.3 % | $ 520 M | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 40.05 | -6.12 % | $ 1.18 B | ||
|
Tandem Diabetes Care
TNDM
|
239 M | $ 12.82 | -9.4 % | $ 872 M |